Whalesbook
Dividend Ka Raaz: Profit Gira, Phir Bhi Bada Payout?
Dekho bhaiyo, Pfizer Ltd. ne FY26 ke liye ₹75 per equity share ka final dividend announce kiya hai, jiska record date July 17, 2026 hai. Yeh sunne mein toh bada achha lag raha hai, hai na? Lekin asli picture thodi alag hai. Company ne Q4 mein apna net profit 39.6% ghata diya hai, jo ab ₹200 crore ho gaya hai (pehle yeh ₹331 crore tha). Toh jab profit itna gir raha hai, company itna bada dividend kaise de rahi hai, yeh sawal pakka uthta hai. Company ka market cap around ₹22,000 crore hai aur trailing P/E ratio mid-20s mein chal raha hai.
Pharma Sector: Chal Toh Raha Hai Par...
Indian pharma sector ki baat karein toh, expect kiya ja raha hai ki FY26 mein yeh 7-9% grow karega. Domestic demand aur exports dono boost kar rahe hain, aur govt bhi local manufacturing ko support kar rahi hai. Lekin sabse bada issue hai rising raw material costs aur supply chain problems, jo profit margins par pressure bana rahe hain. Pfizer bhi isi sector mein hai, par inke apne numbers dikha rahe hain ki inko kuch specific challenges face karne pad rahe hain. Sun Pharma, Divi's Laboratories, Torrent Pharma jaise bade players bhi hain, par unki situation aur dividend policy alag ho sakti hai. Pfizer ka yeh dividend announcement uski 3.5% ki historical average yield se kaafi zyada ho sakta hai.
Profit Kam, Dividend Zyada: Kya Yeh Sustainable Hai?
Yeh sabse critical point hai. Profit mein 39.6% ki giriwat, jo shayad margin squeeze ki wajah se hai, ek bada warning sign hai. Company debt-free hai, balance sheet mazboot hai aur return on equity bhi acchi hai. Par sawal yehi hai ki kya woh apne operating earnings se itna bada dividend consistent de payegi? Revenue growth toh hai, par profit nahi badh raha, matlab operating expenses ya cost of goods sold revenue se zyada tezi se badh rahe hain. Management ko clear karna hoga ki margin squeeze ka reason kya hai – kya yeh ingredient costs ki wajah se hai ya fir new treatments mein kiye gaye investments ki wajah se? Analysts ka outlook bullish hai, ₹6,065 se ₹6,444.67 tak ke price targets hain, jo 28% se 33% ka upside dikha rahe hain. Par yeh haal ke earnings report se thoda alag lag raha hai. Investors ko ab future growth expectations aur is dividend ki appeal ko current profitability pressure ke saath carefully weigh karna hoga.